Related Experiment Video
Updated: Apr 1, 2026
Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer
Published on: May 10, 2024
Clinical utility of ramucirumab in advanced gastric cancer
Matthew Mk Chan1, Katrin M Sjoquist2, John R Zalcberg3
1NHMRC Clinical Trials Centre, University of Sydney, Sydney, NSW, Australia ; Department of Medical Oncology, Central Coast Cancer Centre, Gosford Hospital, Gosford, NSW, Australia.
Abstract:
Gastric cancer is currently the third most common cause of cancer deaths worldwide. Prognosis remains poor with most patients presenting with advanced or metastatic disease. A better understanding of angiogenesis has led to the investigation of drugs that inhibit the vascular endothelial growth factor (VEGF) pathway including anti-VEGF antibody therapy (eg, bevacizumab), inhibitors of angiogenic receptor tyrosine kinases (eg, sunitinib, sorafenib, apatinib, regorafenib), and inhibitors of vascular endothelial growth factor receptors (VEGFRs) (eg, ramucirumab). Ramucirumab, a VEGFR-2 inhibitor, is the first anti-angiogenic agent approved by the US Food and Drug Administration for use in the treatment of advanced gastric cancers. This review will focus on the clinical utility and potential use of ramucirumab in advanced gastric cancer.
Insights
Ramucirumab, a VEGFR-2 inhibitor, offers a new treatment for advanced gastric cancer by targeting angiogenesis. This review explores its clinical use in improving outcomes for patients with this deadly disease.
Area of Science:
- Oncology
- Medical Research
Background:
- Gastric cancer is a leading cause of cancer mortality globally.
- Advanced or metastatic disease is common at diagnosis, leading to poor prognosis.
- Angiogenesis, the formation of new blood vessels, is crucial for tumor growth and metastasis.
Purpose of the Study:
- To review the clinical utility and potential applications of ramucirumab in advanced gastric cancer.
- To discuss ramucirumab as a VEGFR-2 inhibitor targeting the VEGF pathway.
- To highlight ramucirumab's significance as an approved anti-angiogenic therapy for advanced gastric cancer.
Main Methods:
- Review of clinical trials and scientific literature on ramucirumab.
- Analysis of ramucirumab's mechanism of action as a vascular endothelial growth factor receptor-2 (VEGFR-2) inhibitor.
- Evaluation of data supporting the efficacy and safety of ramucirumab in advanced gastric cancer treatment.
Main Results:
- Ramucirumab is the first anti-angiogenic agent approved by the FDA for advanced gastric cancer.
- VEGF pathway inhibitors, including ramucirumab, show promise in targeting tumor angiogenesis.
- Clinical data supports the use of ramucirumab in specific patient populations with advanced gastric cancer.
Conclusions:
- Ramucirumab represents a significant advancement in the treatment of advanced gastric cancer.
- Targeting VEGFR-2 with ramucirumab offers a viable therapeutic strategy.
- Further research may expand the role of ramucirumab in gastric cancer management.
More Related Videos
08:12Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer
Published on: March 14, 2019
10:28Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT
Published on: January 22, 2018
Related Concept Videos
02:56Treatment Resistent Cancers
01:24Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...